The presence of a pathogenic or deleterious mutations in BRCA1 or BRCA2 is associated with a greater risk of developing breast, ovarian, pancreatic, and prostate cancers but are also predictive to response to olaparib. This evidence concerns the gene BRCA1 and Familial prostate cancer.